Showing all 5 results
The NGS Colorectal Cancer Panel from Lab Tests Dubai is a state-of-the-art genetic test that decodes the unique mutations in your tumor, unlocking critical insights for personalized treatment, targeted therapy selection, and hereditary risk assessment.
The **Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 Literature-Reviewed Genes** is a comprehensive genetic test designed to assess hereditary cancer risk. It analyzes **57 key genes**, including the **ACMG 20** and **HBOC-related genes**, alongside **865 literature-reviewed genes**, ensuring a thorough evaluation of cancer predisposition. This panel covers a wide range of hereditary cancers, including **breast, ovarian, colorectal, and more**, providing **clinically actionable insights** for early detection and personalized risk management. Utilizing **advanced sequencing technology**, it delivers **high accuracy and reliability**, making it an essential tool for **patients, healthcare providers, and genetic counselors**. Its unique combination of **expert-curated genes and extensive literature review** enhances diagnostic precision, setting it apart as a **cutting-edge solution for hereditary cancer risk assessment**.
The HALLMARK Liquid Biopsy from Lab Tests Dubai is a groundbreaking, non-invasive test that detects circulating tumor DNA (ctDNA) in your blood, revolutionizing cancer care with a simple blood draw. No surgery, no pain, just powerful insights.
Sample Type : Serum
Methodology : Ultra-deep sequencing using Lucence’s proprietary AmpliMARK™ technology
TAT : 8-10 Days
The Oncomine Acute Myeloid Leukaemia (AML) Panel is a cutting-edge genetic test that provides a full genomic picture of AML, helping doctors pinpoint key mutations, gene fusions, and copy number changes in genes known to drive the disease. Using advanced next-generation sequencing (NGS), this test delivers fast, precise results, even from limited or degraded sample, so patients get an accurate diagnosis and tailored treatment plans sooner.
The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes.